Combination treatment for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial combines a type of immunotherapy (tislelizumab) with chemotherapy and a vitamin A derivative (all-trans retinoic acid) to treat advanced esophageal squamous cell carcinoma. It aims to see if this combination helps shrink or control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with a type of esophageal cancer called squamous cell carcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You have not received any cancer treatment (such as chemotherapy, radiation, or immunotherapy) for this advanced cancer. If you had prior treatment more than 6 months ago and the cancer has come back, you may still be eligible.
- You have at least one tumor that can be measured by scans or exams.
- You are physically active and able to take care of yourself (ECOG score 0 or 1), and your doctor thinks you are likely to live at least 3 more months.
- You do not have certain serious conditions like brain metastases, complete blockage of the esophagus, or a high risk of bleeding or an abnormal connection (fistula) in the esophagus.
- You are not pregnant, not breastfeeding, and you agree to use effective contraception during and for 6 months after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.